Extended Data Fig. 7: Multi-donor iPSC-HLO cholestatic DILI assays.
From: Polygenic architecture informs potential vulnerability to drug-induced liver injury
a, Bright field images of multi-donor iPSC and iPSC-HLO. b, Immunofluorescence staining of Albumin (ALB), BSEP, CD31 and HNF4a in multi-donor iPSC-HLO. c, ALB production during 24 hours in multi-donor iPSC-HLO. Data represent means ± SD (n = 3). d, CYP3A4 activity. Data represent means ± SD (n = 3). e, CLF accumulation and cell death signal in 1383D2 iPSCs derived iPSC-HLOs under CsA treatment for 24hr and 72hr. f, Viability after 24hr (dotted line) and 72hr (black line) CsA treatment in iPSC-HLO model. The ATP levels were normalized by the area of iPSC-HLO (see Materials and Methods).
